Auxier Asset Management Sells 525 Shares of Pfizer Inc. (NYSE:PFE)

Auxier Asset Management reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 0.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 68,253 shares of the biopharmaceutical company’s stock after selling 525 shares during the period. Auxier Asset Management’s holdings in Pfizer were worth $1,975,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Atria Investments Inc boosted its position in Pfizer by 12.1% in the 1st quarter. Atria Investments Inc now owns 274,775 shares of the biopharmaceutical company’s stock valued at $7,626,000 after buying an additional 29,688 shares during the period. Cetera Investment Advisers boosted its holdings in shares of Pfizer by 174.4% in the first quarter. Cetera Investment Advisers now owns 2,202,086 shares of the biopharmaceutical company’s stock valued at $61,108,000 after purchasing an additional 1,399,527 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Pfizer by 39.4% in the first quarter. EverSource Wealth Advisors LLC now owns 25,946 shares of the biopharmaceutical company’s stock valued at $665,000 after purchasing an additional 7,331 shares during the period. IMS Capital Management increased its holdings in Pfizer by 3.3% during the 1st quarter. IMS Capital Management now owns 102,909 shares of the biopharmaceutical company’s stock worth $2,856,000 after purchasing an additional 3,325 shares during the period. Finally, Keynote Financial Services LLC purchased a new position in Pfizer during the 1st quarter worth $1,765,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insiders Place Their Bets

In other news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock opened at $25.83 on Friday. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The business’s fifty day simple moving average is $27.89 and its 200-day simple moving average is $28.51. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market cap of $146.38 billion, a PE ratio of 34.91, a PEG ratio of 0.70 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter last year, the company earned ($0.17) earnings per share. The company’s quarterly revenue was up 31.2% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.50%. Pfizer’s payout ratio is 227.03%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on PFE. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Wolfe Research assumed coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Citigroup assumed coverage on shares of Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective on the stock. Finally, Sanford C. Bernstein assumed coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.